13 June 2022
PRESS RELEASE
Biotech Firm Tackling COVID-19 and M.bovis Announces Successful Development of Rapid, Accurate Johne’s Disease Assay
Auckland-based biotechnology company Pictor Limited has been developing an accurate, affordable multiplexed diagnostic test for Mycobacterium avium paratuberculosis (MAP) – also known as Johne’s disease, that could save the New Zealand dairy industry upwards of $80 million a year in lost production.
“The PictArray™ MAP assay would be a positive addition to national control programs to help in the eradication of Johne’s disease from the dairy industry,” says Pictor’s Director of Research and Development, Dr. Natasha Gordon, who will be presenting at a Johne’s disease conference this week in Dublin, Ireland.
13 April 2022
PRESS RELEASE
Bolstered By Investment, Pictor Partners with Mobility Health to Offer PictArray™ SARS-CoV-2 Antibody Test, Indicating Whether Patients Require COVID-19 Booster
Following a new investment of $6.1 million (NZD $8.8 million), biotech company Pictor today announced a partnership with U.S. laboratory service provider Mobility Health, launching a new antibody test as an important advance in COVID-19 monitoring and treatment. The investment, led by former Morrison & Co CEO Marko Bogoievski, and specialist growth investor K One W One Ltd. (K1W1), will support market and product development of the new antibody test and other Pictor in vitro diagnostics.
20 January 2022
PRESS RELEASE
Pictor Successfully Completes Validation Trial in U.S. for its SARS-CoV-2 Antibody Test
New Zealand diagnostic biotech company Pictor Ltd. announced today that it has successfully completed validation trials at two separate sites in the United States, one of which was Florida-based Boca Biolistics, for its COVID-19 antibody test.
“We were delighted with the performance observed in the Alpha studies which gave us confidence to rapidly proceed with trials in the USA,” said Pictor Chief Technology Officer Dr. Richard Janeczko. “We feel the duplex nature of our test is a unique feature which provides much better data interpretation from serology testing for use the ongoing management of the global pandemic.”
The company now aims to fast-track adoption of its low-cost, high-performance, high-throughput tests by obtaining FDA Emergency Use Authorization.
29 September 2021
PRESS RELEASE
Pictor is excited to announce a strategic collaboration between Pictor and BICO Group’s Scienion for the international commercialisation a high throughput SARS-CoV-2 antibody testing system with Pictor’s SARS-CoV-2 antibody assay and Scienion’s CL2 reader
30 September 2021
PRESS RELEASE
COO, Howard Moore was recently interviewed by National Business Review, regarding the strategic collaboration between Pictor and SCIENION and projected revenue growth for the Company.
27 September 2021
COO, Howard Moore, speaks with Maori TV about their upcoming NZ Clinical trial for their CoVID test which can potentially reduce time visiting whanau spend in MIQ facilities, as well as assist with managing access to vaccine supplies across global vaccination programmes.
20 September 2021
CoVID assay ready for NZ Clinical Trial!
IVD medical expert Tadd S. Lazarus, M.D. speaks with Radio New Zealand’s Kathryn Ryan about our new differentiated CoVID-19 assay
15 September 2021
Watch CEO, Dr Thomas Schlumpberger’s presentation to Wholesale Investors at a recent Venture and Capital Conference.
2 September 2021
IVD medical expert Tadd S. Lazarus, M.D. joins Pictor leadership team as its Consulting Chief Medical Officer.
27 January 2021
Partnership forged to research M. bovis testing kits.
18 August 2020
Patent filed for COVID-19 Multiplex Assay.
In May 2020, Pictor received a $500,000 grant from the New Zealand Government’s MBIE COVID-19 Innovation Acceleration Fund to fast-track the development of a COVID-19 diagnostic assay. Pictor has now filed a patent for that assay.
10 August 2020
Pictor Limited Appoints Dr. Thomas Schlumpberger as Chief Executive Officer.
30 July 2020
Pictor has launched a new funding round to continue developing exciting new products for both human and veterinary health.
29 July 2020
Pictor Welcomes new Product Development Manager as Kiwi returns home after 12 years abroad.
Pictor is delighted to have Dr Natasha Gordon join the New Zealand team as Product Development Manager. Natasha brings a wealth of experience to role, having worked in Europe for the last twelve years in the healthcare and diagnostic space.
Natasha brings twelve years of overseas experience, living and working in Dublin, Ireland. Whilst achieving a PhD in Molecular medicine from the University of Auckland, she developed skills and experience in complement-based protein interaction assays, kinetic binding studies, recombinant protein and antibody development before heading overseas.
During her overseas stint, Natasha gained valuable experience as a deputy quality manager and internal auditor for ISO17025 and led the set-up of the R&D lab for her previous company, Airmid Healthgroup, which went on to publish a number of patents and publications. During her time in this role, Natasha liaised and collaborated with international companies such as Trinity Biotech (IRE/USA), and Biosenia-Kypher (IRE/USA).
Dr Gordon brings a wealth of experience and knowledge to Pictor’s endeavours in the In vitro diagnostic space and Pictor looks forward to utilizing this to make huge strides in future.
“It is exciting to welcome Natasha to the Pictor family. The experience that Natasha brings to Pictor will be invaluable to our efforts to deliver world class diagnostics that improve healthcare access for all” – Howard Moore
2 July 2020
Auckland-based biotechnology company Pictor Limited says it has been developing a multiplex bovine test, via a $404,040 grant from the Ministry for Primary Industries (MPI) Sustainable Food and Fibre Futures Fund.
The test, which is being created in collaboration with Massey University, will initially aim to detect Johne’s Disease and pregnancy from a single milk sample.
18 May 2020
Pictor announces new Global Sales and Marketing Director.
Pictor is delighted to announce that Mr. Sanjay Chakraborty has joined Pictor Executive Management team as Global Sales & Marketing Director. Sanjay brings with him 22 years of rich experience in healthcare & medical devices, having diverse experiences in sales, marketing and business development in India, Middle East, Europe & South America spearheading various businesses in Multi National Organisations.
Pictor announces new Global Sales and Marketing Director.
Pictor is delighted to announce that Mr. Sanjay Chakraborty has joined Pictor Executive Management team as Global Sales & Marketing Director. Sanjay brings with him 22 years of rich experience in healthcare & medical devices, having diverse experiences in sales, marketing and business development in India, Middle East, Europe & South America spearheading various businesses in Multi National Organisations.
Sanjay is an astute sales, marketing and business development professional with 22 years of rich experience in healthcare business, medical equipment, clinical diagnostics and medical devices with a wide global business expertise in 4 continents viz. Indian sub-continent, Asia, Middle East, Europe and South America.
A passionate and dedicated business professional determined to take business to the next level and work relentlessly on strategies to build business from scratch and establish the brand image of an organisation. Has worked with various large American, European and Indian multinational organisations such as Siemens, Godrej Industries, Depuy Synthes (Johnson & Johnson), ConvaTec, Meril Life Sciences in India and Internationally through wholly owned subsidiaries. A team player and has led large teams of Indian and foreign nationals.
Sanjay is an electronics and telecommunication engineer, a PGDBA in marketing management and has successfully completed Executive Management programs in General Management from IIT Bombay and Strategies in International Business from Indian Institute of Foreign Trade, New Delhi.
“Sanjay’s worldwide experience gives us an opportunity to expand and improve upon our current markets, and will enable Pictor to meet its goals of improving healthcare delivery in both a time and financially efficient manner” – Howard Moore
18 May 2020
Pictor receives double funding boost from government and partners for two crucial development projects to help combat COVID-19 and Mycoplasma bovis.
15 May 2020
MPI announces Pictor as a partner for enhancing antibody (ELISA) detection testing as part of their dedication to eradicate and monitor M. bovis within New Zealand.
05 April 2020
Global IVD Director, Dr Sandeep K. Vashist has published an editorial manuscript detailing the current state of in vitro diagnostics for CoVID-19 for the journal Diagnostics.
05 November 2019
Pictor CEO Howard Moore and Pictor Global IVD Director Dr Sandeep Vashist will be attending MEDICA 18-21 Nov, 2019, in Dusseldorf. Please contact Marica at m.vezzoli@pictordx.com or +64 2041261051 if you’d like to get in touch with them.
30 October 2018
We’ve just installed the new Pictor Diagnostics System at Siddhivinayak Pathology Laboratory. We look forward to working with Dr Rashmi Rahangdale and Dr Pawan Singh Rahangdale.
15 October 2018
We are happy to introduce J.J. Diagnostic Pvt. Ltd in Ambikapur as our new customer.
10 October 2018
Pictor has successfully been certified for ISO 13485:2016.
4 October 2018
Pictor is attending the 5th International Conference on Gynecology and Obstetrics in Zurich, Switzerland.